Alnylam Pharmaceuticals Inc.
) recently entered into an exclusive global alliance with
The Medicines Company
) for the development and commercialization of the prior's
ALN-PCS ribo nucleic acid interference (RNAi) therapeutic
Currently under development for the treatment of
hypercholesterolemia, ALN-PCS RNAi is an important program in
Alnylam's "Alnylam 5x15" strategy.
As per the terms of the collaboration agreement, The Medicines
Company will be making an upfront cash payment of $25 million to
Alnylam. Alnylam is also eligible to receive up to $180 million
on the achievement of development and commercial milestones. The
company could also receive scaled double-digit royalties from The
Medicines Company on global products sales of the ALN-PCS
products commercialized under this agreement.
The collaboration includes ALN-PCS02 and ALN-PCSsc. ALN-PCS02
is an intravenous RNAi therapeutic which completed a phase I
trial, whereas ALN-PCSsc, a subcutaneously administered RNAi
therapeutic, is currently in pre-clinical development.
Meanwhile, Alnylam is expected to continue with its ALN-PCS
program for another one to two years to complete certain
pre-clinical and phase I studies. The Medicines Company will be
responsible for the development of the candidates from phase II
onwards. The Medicines Company will also be responsible for the
commercialization of the candidates if the ALN-PCS program is
Earlier this year, Alnylam had provided a brief update on its
key "Alnylam 5x15" pipeline, which aims to develop RNAi
therapeutic candidates and partner programs for the next couple
of years. The company is expecting several study results based on
its RNAi therapeutic candidates in the next two years.
We believe that the company is progressing well with its
"Alnylam 5x15" pipeline. We expect investor focus to stay on the
successful development of the pipeline, though most of them are
in early stages of development.
Alnylam carries a Zacks Rank #4 (Sell). However, other
biopharmaceutical stocks such as
) carry a Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy)
ALNYLAM PHARMA (ALNY): Free Stock Analysis
MEDICINES CO (MDCO): Free Stock Analysis
MEDIVATION INC (MDVN): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
To read this article on Zacks.com click here.